TOT BIOPHARM Announces Board Changes with New Director Appointments

TOT BIOPHARM International Co. Ltd. ( (HK:1875) ) has shared an update.

TOT BIOPHARM International Co. Ltd. announced changes in its board of directors and board committees, effective March 12, 2025. Three independent non-executive directors, Ms. Hu Lan, Mr. Chang Hong-Jen, and Dr. Wang De Qian, have resigned due to the expiration of their terms and personal commitments. The company has appointed Ms. Sun Hui, Mr. Zhang Qing, and Dr. Gu Xuelin as new independent non-executive directors, bringing extensive experience in accounting, financial management, and capital markets to the board. These changes are expected to bring fresh perspectives and strengthen the company’s governance as it continues to focus on its strategic goals.

More about TOT BIOPHARM International Co. Ltd.

TOT BIOPHARM International Co. Ltd. operates in the biopharmaceutical industry, focusing on the development, manufacturing, and commercialization of oncology drugs. The company is positioned in the market to address the growing demand for innovative cancer therapies.

YTD Price Performance: 17.32%

Average Trading Volume: 107,991

Technical Sentiment Consensus Rating: Sell

Current Market Cap: HK$1.62B

For an in-depth examination of 1875 stock, go to TipRanks’ Stock Analysis page.